Drug Trial Radar · NCT07362992
Topical Tranexamic Acid to Reduce Blood Loss During Cesarean Delivery
Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
112
Planned (sponsor's estimate)
Start
Jul 1, 2026
Primary completion
Dec 1, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Wolfson Medical CenterGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- Rabin Medical Center; Meir Medical Center; Kaplan Medical Center
- First posted
- Jan 23, 2026
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 51 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn whether applying topical tranexamic acid (TXA) directly to the uterine incision during cesarean delivery can reduce surgical bleeding compared to placebo. The study will include pregnant women aged 18-51 undergoing elective cesarean delivery at term (37 weeks or more). The main questions it aims to answer are: * Does topical TXA shorten uterine closure time? * Does topical TXA reduce the need for additional hemostatic sutures? Researchers will compare women receiving topical TXA to those receiving placebo (normal saline) to see if TXA reduces intraoperative bleeding and improves surgical outcomes. Participants will: * Be randomly assigned to receive either topical TXA or placebo during cesarean delivery. * Have standard surgery and postoperative care identical in both groups. * Provide routine clinical data, including hemoglobin levels and recovery outcomes, from their medical records.
Conditions
- Cesarean Delivery
- Postpartum Hemorrhage (PPH)
- Intraoperative Blood Loss
- Hemostasis
Interventions
Tranexamic Acid (Topical)Drug
This intervention involves topical application of tranexamic acid (TXA) directly to the uterine incision during cesarean delivery, rather than the conventional intravenous route. A solution containing 500 mg of TXA (one ampule, 5 mL) diluted in 15 mL of normal saline is sprayed evenly over the uterine incision surface after placental delivery and before suturing. A second application of the same solution is sprayed before the second layer of uterine closure. This localized, site-directed use is designed to reduce intraoperative bleeding with minimal systemic absorption, distinguishing it from previously studied intravenous TXA regimens.
Normal Saline (Placebo)Other
This comparator intervention involves topical application of sterile normal saline to the uterine incision at the same time points as in the TXA arm - after placental delivery and before each layer of uterine closure. This placebo control enables a direct comparison to determine whether the topical TXA application provides added benefit in reducing intraoperative bleeding.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Uterine closure time (minutes)Time frame: Intraoperative (during the index cesarean delivery)
- Number of additional hemostatic sutures (count)Time frame: Intraoperative (during the index cesarean delivery)
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Meir medical center
Kfar Saba, Israel · Not yet recruiting
Rabin medical center
Petah Tikva, Israel · Not yet recruiting
Kaplan medical center
Rehovot, Israel · Not yet recruiting
Edith Wolfson Medical Center
Holon, Central District, Israel · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.